APO Research
Talk to an analyst

APO RESEARCH · REPORT

Treatment for Accelerated-Phase CML

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Treatment for Accelerated-Phase CML Market Analysis and Forecast 2026-2032

27 December 2025193 pages

Choose your research edition.

Industry ResearchTreatment for Accelerated-Phase CML Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Treatment for Accelerated-Phase CML Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal Treatment for Accelerated-Phase CML Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Treatment for Accelerated-Phase CML Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Treatment for Accelerated-Phase CML Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Treatment for Accelerated-Phase CML market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Treatment for Accelerated-Phase CML is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Treatment for Accelerated-Phase CML is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Treatment for Accelerated-Phase CML is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Treatment for Accelerated-Phase CML is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Treatment for Accelerated-Phase CML include Apotex, Bristol Myers Squibb, Dr. Reddy's Laboratories, Novartis, Pfizer, Takeda Pharmaceuticals, Lunan Pharmaceutical, Qilu Pharmaceutical and CSPC Ouyi Pharmaceutical, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Treatment for Accelerated-Phase CML, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Treatment for Accelerated-Phase CML, also provides the sales of main regions and countries. Of the upcoming market potential for Treatment for Accelerated-Phase CML, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Treatment for Accelerated-Phase CML sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Treatment for Accelerated-Phase CML market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Treatment for Accelerated-Phase CML sales, projected growth trends, production technology, application and end-user industry.

Treatment for Accelerated-Phase CML Segment by Company

Apotex

Bristol Myers Squibb

Dr. Reddy's Laboratories

Novartis

Pfizer

Takeda Pharmaceuticals

Lunan Pharmaceutical

Qilu Pharmaceutical

CSPC Ouyi Pharmaceutical

Chia Tai Tianqing Pharmaceutical

Treatment for Accelerated-Phase CML Segment by Type

Tyrosine Kinase Inhibitors

Allogeneic Stem Cell Transplantation

Others

Treatment for Accelerated-Phase CML Segment by Application

Hospitals

Clinics

Others

Treatment for Accelerated-Phase CML Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Treatment for Accelerated-Phase CML market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Treatment for Accelerated-Phase CML and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Treatment for Accelerated-Phase CML.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Treatment for Accelerated-Phase CML in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Treatment for Accelerated-Phase CML manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Treatment for Accelerated-Phase CML sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Treatment for Accelerated-Phase CML Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Tyrosine Kinase Inhibitors Major Manufacturers Table 3. Allogeneic Stem Cell Transplantation Major Manufacturers Table 4. Others Major Manufacturers Table 5. Global Treatment for Accelerated-Phase CML Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospitals Major Manufacturers Table 7. Clinics Major Manufacturers Table 8. Others Major Manufacturers Table 9. Treatment for Accelerated-Phase CML Industry Trends Table 10. Treatment for Accelerated-Phase CML Industry Drivers Table 11. Treatment for Accelerated-Phase CML Industry Opportunities and Challenges Table 12. Treatment for Accelerated-Phase CML Industry Restraints Table 13. Global Treatment for Accelerated-Phase CML Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 14. Global Treatment for Accelerated-Phase CML Revenue by Region (2021-2026) & (US$ Million) Table 15. Global Treatment for Accelerated-Phase CML Revenue by Region (2027-2032) & (US$ Million) Table 16. Global Treatment for Accelerated-Phase CML Revenue Market Share by Region (2021-2026) Table 17. Global Treatment for Accelerated-Phase CML Revenue Market Share by Region (2027-2032) Table 18. Global Treatment for Accelerated-Phase CML Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 19. Global Treatment for Accelerated-Phase CML Sales by Region (2021-2026) & (K Units) Table 20. Global Treatment for Accelerated-Phase CML Sales by Region (2027-2032) & (K Units) Table 21. Global Treatment for Accelerated-Phase CML Sales Market Share by Region (2021-2026) Table 22. Global Treatment for Accelerated-Phase CML Sales Market Share by Region (2027-2032) Table 23. Global Treatment for Accelerated-Phase CML Revenue by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Treatment for Accelerated-Phase CML Revenue Market Share by Manufacturers (2021-2026) Table 25. Global Treatment for Accelerated-Phase CML Sales by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Treatment for Accelerated-Phase CML Sales Market Share by Manufacturers (2021-2026) Table 27. Global Treatment for Accelerated-Phase CML Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 28. Global Treatment for Accelerated-Phase CML Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 29. Global Treatment for Accelerated-Phase CML Key Manufacturers Manufacturing Sites & Headquarters Table 30. Global Treatment for Accelerated-Phase CML Manufacturers, Product Type & Application Table 31. Global Treatment for Accelerated-Phase CML Manufacturers' Establishment Date Table 32. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 33. Global Treatment for Accelerated-Phase CML by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 34. Global Treatment for Accelerated-Phase CML Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Treatment for Accelerated-Phase CML Revenue by Type (2021-2026) & (US$ Million) Table 36. Global Treatment for Accelerated-Phase CML Revenue by Type (2027-2032) & (US$ Million) Table 37. Global Treatment for Accelerated-Phase CML Revenue Market Share by Type (2021-2026) Table 38. Global Treatment for Accelerated-Phase CML Revenue Market Share by Type (2027-2032) Table 39. Global Treatment for Accelerated-Phase CML Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 40. Global Treatment for Accelerated-Phase CML Sales by Type (2021-2026) & (K Units) Table 41. Global Treatment for Accelerated-Phase CML Sales by Type (2027-2032) & (K Units) Table 42. Global Treatment for Accelerated-Phase CML Sales Market Share by Type (2021-2026) Table 43. Global Treatment for Accelerated-Phase CML Sales Market Share by Type (2027-2032) Table 44. Global Treatment for Accelerated-Phase CML Price by Type (2021-2026) & (US$/Unit) Table 45. Global Treatment for Accelerated-Phase CML Price by Type (2027-2032) & (US$/Unit) Table 46. Global Treatment for Accelerated-Phase CML Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Treatment for Accelerated-Phase CML Revenue by Application (2021-2026) & (US$ Million) Table 48. Global Treatment for Accelerated-Phase CML Revenue by Application (2027-2032) & (US$ Million) Table 49. Global Treatment for Accelerated-Phase CML Revenue Market Share by Application (2021-2026) Table 50. Global Treatment for Accelerated-Phase CML Revenue Market Share by Application (2027-2032) Table 51. Global Treatment for Accelerated-Phase CML Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 52. Global Treatment for Accelerated-Phase CML Sales by Application (2021-2026) & (K Units) Table 53. Global Treatment for Accelerated-Phase CML Sales by Application (2027-2032) & (K Units) Table 54. Global Treatment for Accelerated-Phase CML Sales Market Share by Application (2021-2026) Table 55. Global Treatment for Accelerated-Phase CML Sales Market Share by Application (2027-2032) Table 56. Global Treatment for Accelerated-Phase CML Price by Application (2021-2026) & (US$/Unit) Table 57. Global Treatment for Accelerated-Phase CML Price by Application (2027-2032) & (US$/Unit) Table 58. Apotex Company Information Table 59. Apotex Business Overview Table 60. Apotex Treatment for Accelerated-Phase CML Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Apotex Treatment for Accelerated-Phase CML Product Portfolio Table 62. Apotex Recent Development Table 63. Bristol Myers Squibb Company Information Table 64. Bristol Myers Squibb Business Overview Table 65. Bristol Myers Squibb Treatment for Accelerated-Phase CML Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Bristol Myers Squibb Treatment for Accelerated-Phase CML Product Portfolio Table 67. Bristol Myers Squibb Recent Development Table 68. Dr. Reddy's Laboratories Company Information Table 69. Dr. Reddy's Laboratories Business Overview Table 70. Dr. Reddy's Laboratories Treatment for Accelerated-Phase CML Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Dr. Reddy's Laboratories Treatment for Accelerated-Phase CML Product Portfolio Table 72. Dr. Reddy's Laboratories Recent Development Table 73. Novartis Company Information Table 74. Novartis Business Overview Table 75. Novartis Treatment for Accelerated-Phase CML Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Novartis Treatment for Accelerated-Phase CML Product Portfolio Table 77. Novartis Recent Development Table 78. Pfizer Company Information Table 79. Pfizer Business Overview Table 80. Pfizer Treatment for Accelerated-Phase CML Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Pfizer Treatment for Accelerated-Phase CML Product Portfolio Table 82. Pfizer Recent Development Table 83. Takeda Pharmaceuticals Company Information Table 84. Takeda Pharmaceuticals Business Overview Table 85. Takeda Pharmaceuticals Treatment for Accelerated-Phase CML Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Takeda Pharmaceuticals Treatment for Accelerated-Phase CML Product Portfolio Table 87. Takeda Pharmaceuticals Recent Development Table 88. Lunan Pharmaceutical Company Information Table 89. Lunan Pharmaceutical Business Overview Table 90. Lunan Pharmaceutical Treatment for Accelerated-Phase CML Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Lunan Pharmaceutical Treatment for Accelerated-Phase CML Product Portfolio Table 92. Lunan Pharmaceutical Recent Development Table 93. Qilu Pharmaceutical Company Information Table 94. Qilu Pharmaceutical Business Overview Table 95. Qilu Pharmaceutical Treatment for Accelerated-Phase CML Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Qilu Pharmaceutical Treatment for Accelerated-Phase CML Product Portfolio Table 97. Qilu Pharmaceutical Recent Development Table 98. CSPC Ouyi Pharmaceutical Company Information Table 99. CSPC Ouyi Pharmaceutical Business Overview Table 100. CSPC Ouyi Pharmaceutical Treatment for Accelerated-Phase CML Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. CSPC Ouyi Pharmaceutical Treatment for Accelerated-Phase CML Product Portfolio Table 102. CSPC Ouyi Pharmaceutical Recent Development Table 103. Chia Tai Tianqing Pharmaceutical Company Information Table 104. Chia Tai Tianqing Pharmaceutical Business Overview Table 105. Chia Tai Tianqing Pharmaceutical Treatment for Accelerated-Phase CML Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Chia Tai Tianqing Pharmaceutical Treatment for Accelerated-Phase CML Product Portfolio Table 107. Chia Tai Tianqing Pharmaceutical Recent Development Table 108. North America Treatment for Accelerated-Phase CML Revenue by Type (2021-2026) & (US$ Million) Table 109. North America Treatment for Accelerated-Phase CML Revenue by Type (2027-2032) & (US$ Million) Table 110. North America Treatment for Accelerated-Phase CML Sales by Type (2021-2026) & (K Units) Table 111. North America Treatment for Accelerated-Phase CML Sales by Type (2027-2032) & (K Units) Table 112. North America Treatment for Accelerated-Phase CML Sales Price by Type (2021-2026) & (US$/Unit) Table 113. North America Treatment for Accelerated-Phase CML Sales Price by Type (2027-2032) & (US$/Unit) Table 114. North America Treatment for Accelerated-Phase CML Revenue by Application (2021-2026) & (US$ Million) Table 115. North America Treatment for Accelerated-Phase CML Revenue by Application (2027-2032) & (US$ Million) Table 116. North America Treatment for Accelerated-Phase CML Sales by Application (2021-2026) & (K Units) Table 117. North America Treatment for Accelerated-Phase CML Sales by Application (2027-2032) & (K Units) Table 118. North America Treatment for Accelerated-Phase CML Sales Price by Application (2021-2026) & (US$/Unit) Table 119. North America Treatment for Accelerated-Phase CML Sales Price by Application (2027-2032) & (US$/Unit) Table 120. North America Treatment for Accelerated-Phase CML Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 121. North America Treatment for Accelerated-Phase CML Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 122. North America Treatment for Accelerated-Phase CML Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 123. North America Treatment for Accelerated-Phase CML Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 124. North America Treatment for Accelerated-Phase CML Sales by Country (2021-2026) & (K Units) Table 125. North America Treatment for Accelerated-Phase CML Sales by Country (2027-2032) & (K Units) Table 126. North America Treatment for Accelerated-Phase CML Sales Price by Country (2021-2026) & (US$/Unit) Table 127. North America Treatment for Accelerated-Phase CML Sales Price by Country (2027-2032) & (US$/Unit) Table 128. United States Treatment for Accelerated-Phase CML Revenue (2021-2032) & (US$ Million) Table 129. Canada Treatment for Accelerated-Phase CML Revenue (2021-2032) & (US$ Million) Table 130. Mexico Treatment for Accelerated-Phase CML Revenue (2021-2032) & (US$ Million) Table 131. Europe Treatment for Accelerated-Phase CML Revenue by Type (2021-2026) & (US$ Million) Table 132. Europe Treatment for Accelerated-Phase CML Revenue by Type (2027-2032) & (US$ Million) Table 133. Europe Treatment for Accelerated-Phase CML Sales by Type (2021-2026) & (K Units) Table 134. Europe Treatment for Accelerated-Phase CML Sales by Type (2027-2032) & (K Units) Table 135. Europe Treatment for Accelerated-Phase CML Sales Price by Type (2021-2026) & (US$/Unit) Table 136. Europe Treatment for Accelerated-Phase CML Sales Price by Type (2027-2032) & (US$/Unit) Table 137. Europe Treatment for Accelerated-Phase CML Revenue by Application (2021-2026) & (US$ Million) Table 138. Europe Treatment for Accelerated-Phase CML Revenue by Application (2027-2032) & (US$ Million) Table 139. Europe Treatment for Accelerated-Phase CML Sales by Application (2021-2026) & (K Units) Table 140. Europe Treatment for Accelerated-Phase CML Sales by Application (2027-2032) & (K Units) Table 141. Europe Treatment for Accelerated-Phase CML Sales Price by Application (2021-2026) & (US$/Unit) Table 142. Europe Treatment for Accelerated-Phase CML Sales Price by Application (2027-2032) & (US$/Unit) Table 143. Europe Treatment for Accelerated-Phase CML Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 144. Europe Treatment for Accelerated-Phase CML Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 145. Europe Treatment for Accelerated-Phase CML Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 146. Europe Treatment for Accelerated-Phase CML Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 147. Europe Treatment for Accelerated-Phase CML Sales by Country (2021-2026) & (K Units) Table 148. Europe Treatment for Accelerated-Phase CML Sales by Country (2027-2032) & (K Units) Table 149. Europe Treatment for Accelerated-Phase CML Sales Price by Country (2021-2026) & (US$/Unit) Table 150. Europe Treatment for Accelerated-Phase CML Sales Price by Country (2027-2032) & (US$/Unit) Table 151. Germany Treatment for Accelerated-Phase CML Revenue (2021-2032) & (US$ Million) Table 152. France Treatment for Accelerated-Phase CML Revenue (2021-2032) & (US$ Million) Table 153. U.K. Treatment for Accelerated-Phase CML Revenue (2021-2032) & (US$ Million) Table 154. Italy Treatment for Accelerated-Phase CML Revenue (2021-2032) & (US$ Million) Table 155. Russia Treatment for Accelerated-Phase CML Revenue (2021-2032) & (US$ Million) Table 156. Spain Treatment for Accelerated-Phase CML Revenue (2021-2032) & (US$ Million) Table 157. Netherlands Treatment for Accelerated-Phase CML Revenue (2021-2032) & (US$ Million) Table 158. Switzerland Treatment for Accelerated-Phase CML Revenue (2021-2032) & (US$ Million) Table 159. Sweden Treatment for Accelerated-Phase CML Revenue (2021-2032) & (US$ Million) Table 160. Poland Treatment for Accelerated-Phase CML Revenue (2021-2032) & (US$ Million) Table 161. China Treatment for Accelerated-Phase CML Revenue by Type (2021-2026) & (US$ Million) Table 162. China Treatment for Accelerated-Phase CML Revenue by Type (2027-2032) & (US$ Million) Table 163. China Treatment for Accelerated-Phase CML Sales by Type (2021-2026) & (K Units) Table 164. China Treatment for Accelerated-Phase CML Sales by Type (2027-2032) & (K Units) Table 165. China Treatment for Accelerated-Phase CML Sales Price by Type (2021-2026) & (US$/Unit) Table 166. China Treatment for Accelerated-Phase CML Sales Price by Type (2027-2032) & (US$/Unit) Table 167. China Treatment for Accelerated-Phase CML Revenue by Application (2021-2026) & (US$ Million) Table 168. China Treatment for Accelerated-Phase CML Revenue by Application (2027-2032) & (US$ Million) Table 169. China Treatment for Accelerated-Phase CML Sales by Application (2021-2026) & (K Units) Table 170. China Treatment for Accelerated-Phase CML Sales by Application (2027-2032) & (K Units) Table 171. China Treatment for Accelerated-Phase CML Sales Price by Application (2021-2026) & (US$/Unit) Table 172. China Treatment for Accelerated-Phase CML Sales Price by Application (2027-2032) & (US$/Unit) Table 173. Asia Treatment for Accelerated-Phase CML Revenue by Type (2021-2026) & (US$ Million) Table 174. Asia Treatment for Accelerated-Phase CML Revenue by Type (2027-2032) & (US$ Million) Table 175. Asia Treatment for Accelerated-Phase CML Sales by Type (2021-2026) & (K Units) Table 176. Asia Treatment for Accelerated-Phase CML Sales by Type (2027-2032) & (K Units) Table 177. Asia Treatment for Accelerated-Phase CML Sales Price by Type (2021-2026) & (US$/Unit) Table 178. Asia Treatment for Accelerated-Phase CML Sales Price by Type (2027-2032) & (US$/Unit) Table 179. Asia Treatment for Accelerated-Phase CML Revenue by Application (2021-2026) & (US$ Million) Table 180. Asia Treatment for Accelerated-Phase CML Revenue by Application (2027-2032) & (US$ Million) Table 181. Asia Treatment for Accelerated-Phase CML Sales by Application (2021-2026) & (K Units) Table 182. Asia Treatment for Accelerated-Phase CML Sales by Application (2027-2032) & (K Units) Table 183. Asia Treatment for Accelerated-Phase CML Sales Price by Application (2021-2026) & (US$/Unit) Table 184. Asia Treatment for Accelerated-Phase CML Sales Price by Application (2027-2032) & (US$/Unit) Table 185. Asia Treatment for Accelerated-Phase CML Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 186. Asia Treatment for Accelerated-Phase CML Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 187. Asia Treatment for Accelerated-Phase CML Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 188. Asia Treatment for Accelerated-Phase CML Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 189. Asia Treatment for Accelerated-Phase CML Sales by Country (2021-2026) & (K Units) Table 190. Asia Treatment for Accelerated-Phase CML Sales by Country (2027-2032) & (K Units) Table 191. Asia Treatment for Accelerated-Phase CML Sales Price by Country (2021-2026) & (US$/Unit) Table 192. Asia Treatment for Accelerated-Phase CML Sales Price by Country (2027-2032) & (US$/Unit) Table 193. Japan Treatment for Accelerated-Phase CML Revenue (2021-2032) & (US$ Million) Table 194. South Korea Treatment for Accelerated-Phase CML Revenue (2021-2032) & (US$ Million) Table 195. India Treatment for Accelerated-Phase CML Revenue (2021-2032) & (US$ Million) Table 196. Australia Treatment for Accelerated-Phase CML Revenue (2021-2032) & (US$ Million) Table 197. Taiwan Treatment for Accelerated-Phase CML Revenue (2021-2032) & (US$ Million) Table 198. Southeast Asia Treatment for Accelerated-Phase CML Revenue (2021-2032) & (US$ Million) Table 199. SAMEA Treatment for Accelerated-Phase CML Revenue by Type (2021-2026) & (US$ Million) Table 200. SAMEA Treatment for Accelerated-Phase CML Revenue by Type (2027-2032) & (US$ Million) Table 201. SAMEA Treatment for Accelerated-Phase CML Sales by Type (2021-2026) & (K Units) Table 202. SAMEA Treatment for Accelerated-Phase CML Sales by Type (2027-2032) & (K Units) Table 203. SAMEA Treatment for Accelerated-Phase CML Sales Price by Type (2021-2026) & (US$/Unit) Table 204. SAMEA Treatment for Accelerated-Phase CML Sales Price by Type (2027-2032) & (US$/Unit) Table 205. SAMEA Treatment for Accelerated-Phase CML Revenue by Application (2021-2026) & (US$ Million) Table 206. SAMEA Treatment for Accelerated-Phase CML Revenue by Application (2027-2032) & (US$ Million) Table 207. SAMEA Treatment for Accelerated-Phase CML Sales by Application (2021-2026) & (K Units) Table 208. SAMEA Treatment for Accelerated-Phase CML Sales by Application (2027-2032) & (K Units) Table 209. SAMEA Treatment for Accelerated-Phase CML Sales Price by Application (2021-2026) & (US$/Unit) Table 210. SAMEA Treatment for Accelerated-Phase CML Sales Price by Application (2027-2032) & (US$/Unit) Table 211. SAMEA Treatment for Accelerated-Phase CML Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 212. SAMEA Treatment for Accelerated-Phase CML Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 213. SAMEA Treatment for Accelerated-Phase CML Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 214. SAMEA Treatment for Accelerated-Phase CML Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 215. SAMEA Treatment for Accelerated-Phase CML Sales by Country (2021-2026) & (K Units) Table 216. SAMEA Treatment for Accelerated-Phase CML Sales by Country (2027-2032) & (K Units) Table 217. SAMEA Treatment for Accelerated-Phase CML Sales Price by Country (2021-2026) & (US$/Unit) Table 218. SAMEA Treatment for Accelerated-Phase CML Sales Price by Country (2027-2032) & (US$/Unit) Table 219. Brazil Treatment for Accelerated-Phase CML Revenue (2021-2032) & (US$ Million) Table 220. Argentina Treatment for Accelerated-Phase CML Revenue (2021-2032) & (US$ Million) Table 221. Chile Treatment for Accelerated-Phase CML Revenue (2021-2032) & (US$ Million) Table 222. Colombia Treatment for Accelerated-Phase CML Revenue (2021-2032) & (US$ Million) Table 223. Peru Treatment for Accelerated-Phase CML Revenue (2021-2032) & (US$ Million) Table 224. Saudi Arabia Treatment for Accelerated-Phase CML Revenue (2021-2032) & (US$ Million) Table 225. Israel Treatment for Accelerated-Phase CML Revenue (2021-2032) & (US$ Million) Table 226. UAE Treatment for Accelerated-Phase CML Revenue (2021-2032) & (US$ Million) Table 227. Turkey Treatment for Accelerated-Phase CML Revenue (2021-2032) & (US$ Million) Table 228. Iran Treatment for Accelerated-Phase CML Revenue (2021-2032) & (US$ Million) Table 229. Egypt Treatment for Accelerated-Phase CML Revenue (2021-2032) & (US$ Million) Table 230. Key Raw Materials Table 231. Raw Materials Key Suppliers Table 232. Treatment for Accelerated-Phase CML Distributors List Table 233. Treatment for Accelerated-Phase CML Customers List Table 234. Research Programs/Design for This Report Table 235. Authors List of This Report Table 236. Secondary Sources Table 237. Primary Sources List of Figures Figure 1. Treatment for Accelerated-Phase CML Image Figure 2. Global Treatment for Accelerated-Phase CML Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Treatment for Accelerated-Phase CML Market Size Share 2021 VS 2025 VS 2032 Figure 4. Tyrosine Kinase Inhibitors Image Figure 5. Allogeneic Stem Cell Transplantation Image Figure 6. Others Image Figure 7. Global Treatment for Accelerated-Phase CML Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Treatment for Accelerated-Phase CML Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospitals Image Figure 10. Clinics Image Figure 11. Others Image Figure 12. Global Treatment for Accelerated-Phase CML Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Treatment for Accelerated-Phase CML Revenue (2021-2032) & (US$ Million) Figure 14. Global Treatment for Accelerated-Phase CML Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 15. Global Treatment for Accelerated-Phase CML Revenue Market Share by Region: 2025 Versus 2032 Figure 16. Global Treatment for Accelerated-Phase CML Revenue Market Share by Region (2021-2032) Figure 17. Global Treatment for Accelerated-Phase CML Sales (2021-2032) & (K Units) Figure 18. Global Treatment for Accelerated-Phase CML Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 19. Global Treatment for Accelerated-Phase CML Sales Market Share by Region (2021-2032) Figure 20. US & Canada & Mexico Treatment for Accelerated-Phase CML Sales YoY (2021-2032) & (K Units) Figure 21. Europe Treatment for Accelerated-Phase CML Sales YoY (2021-2032) & (K Units) Figure 22. China Treatment for Accelerated-Phase CML Sales YoY (2021-2032) & (K Units) Figure 23. Asia (Excluding China) Treatment for Accelerated-Phase CML Sales YoY (2021-2032) & (K Units) Figure 24. South America, Middle East and Africa Treatment for Accelerated-Phase CML Sales YoY (2021-2032) & (K Units) Figure 25. Global Treatment for Accelerated-Phase CML Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 26. Global Treatment for Accelerated-Phase CML Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 27. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 28. Global Treatment for Accelerated-Phase CML Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Treatment for Accelerated-Phase CML Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 30. Global Treatment for Accelerated-Phase CML Revenue Market Share by Type (2021-2032) Figure 31. Global Treatment for Accelerated-Phase CML Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 32. Global Treatment for Accelerated-Phase CML Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Treatment for Accelerated-Phase CML Sales Market Share by Type (2021-2032) Figure 34. Global Treatment for Accelerated-Phase CML Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 35. Global Treatment for Accelerated-Phase CML Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 36. Global Treatment for Accelerated-Phase CML Revenue Market Share by Application (2021-2032) Figure 37. Global Treatment for Accelerated-Phase CML Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 38. Global Treatment for Accelerated-Phase CML Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Treatment for Accelerated-Phase CML Sales Market Share by Application (2021-2032) Figure 40. North America Treatment for Accelerated-Phase CML Revenue Share by Type (2021-2032) Figure 41. North America Treatment for Accelerated-Phase CML Sales Share by Type (2021-2032) Figure 42. North America Treatment for Accelerated-Phase CML Revenue Share by Application (2021-2032) Figure 43. North America Treatment for Accelerated-Phase CML Sales Share by Application (2021-2032) Figure 44. North America Treatment for Accelerated-Phase CML Revenue Share by Country (2021-2032) Figure 45. North America Treatment for Accelerated-Phase CML Sales Share by Country (2021-2032) Figure 46. Europe Treatment for Accelerated-Phase CML Revenue Share by Type (2021-2032) Figure 47. Europe Treatment for Accelerated-Phase CML Sales Share by Type (2021-2032) Figure 48. Europe Treatment for Accelerated-Phase CML Revenue Share by Application (2021-2032) Figure 49. Europe Treatment for Accelerated-Phase CML Sales Share by Application (2021-2032) Figure 50. Europe Treatment for Accelerated-Phase CML Revenue Share by Country (2021-2032) Figure 51. Europe Treatment for Accelerated-Phase CML Sales Share by Country (2021-2032) Figure 52. China Treatment for Accelerated-Phase CML Revenue Share by Type (2021-2032) Figure 53. China Treatment for Accelerated-Phase CML Sales Share by Type (2021-2032) Figure 54. China Treatment for Accelerated-Phase CML Revenue Share by Application (2021-2032) Figure 55. China Treatment for Accelerated-Phase CML Sales Share by Application (2021-2032) Figure 56. Asia Treatment for Accelerated-Phase CML Revenue Share by Type (2021-2032) Figure 57. Asia Treatment for Accelerated-Phase CML Sales Share by Type (2021-2032) Figure 58. Asia Treatment for Accelerated-Phase CML Revenue Share by Application (2021-2032) Figure 59. Asia Treatment for Accelerated-Phase CML Sales Share by Application (2021-2032) Figure 60. Asia Treatment for Accelerated-Phase CML Revenue Share by Country (2021-2032) Figure 61. Asia Treatment for Accelerated-Phase CML Sales Share by Country (2021-2032) Figure 62. SAMEA Treatment for Accelerated-Phase CML Revenue Share by Type (2021-2032) Figure 63. SAMEA Treatment for Accelerated-Phase CML Sales Share by Type (2021-2032) Figure 64. SAMEA Treatment for Accelerated-Phase CML Revenue Share by Application (2021-2032) Figure 65. SAMEA Treatment for Accelerated-Phase CML Sales Share by Application (2021-2032) Figure 66. SAMEA Treatment for Accelerated-Phase CML Revenue Share by Country (2021-2032) Figure 67. SAMEA Treatment for Accelerated-Phase CML Sales Share by Country (2021-2032) Figure 68. Treatment for Accelerated-Phase CML Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Treatment for Accelerated-Phase CML Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Tyrosine Kinase Inhibitors
  • Allogeneic Stem Cell Transplantation
  • Others
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Apotex
  • Bristol Myers Squibb
  • Dr. Reddy's Laboratories
  • Novartis
  • Pfizer
  • Takeda Pharmaceuticals
  • Lunan Pharmaceutical
  • Qilu Pharmaceutical
  • CSPC Ouyi Pharmaceutical
  • Chia Tai Tianqing Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Treatment for Accelerated-Phase CML Market by Type
  3. 1.2.1 Global Treatment for Accelerated-Phase CML Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Tyrosine Kinase Inhibitors
  5. 1.2.3 Allogeneic Stem Cell Transplantation
  6. 1.2.4 Others
  7. 1.3 Treatment for Accelerated-Phase CML Market by Application
  8. 1.3.1 Global Treatment for Accelerated-Phase CML Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospitals
  10. 1.3.3 Clinics
  11. 1.3.4 Others
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Treatment for Accelerated-Phase CML Market Dynamics
  1. 2.1 Treatment for Accelerated-Phase CML Industry Trends
  2. 2.2 Treatment for Accelerated-Phase CML Industry Drivers
  3. 2.3 Treatment for Accelerated-Phase CML Industry Opportunities and Challenges
  4. 2.4 Treatment for Accelerated-Phase CML Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Treatment for Accelerated-Phase CML Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Treatment for Accelerated-Phase CML Revenue by Region
  3. 3.2.1 Global Treatment for Accelerated-Phase CML Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Treatment for Accelerated-Phase CML Revenue by Region (2021-2026)
  5. 3.2.3 Global Treatment for Accelerated-Phase CML Revenue by Region (2027-2032)
  6. 3.2.4 Global Treatment for Accelerated-Phase CML Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Treatment for Accelerated-Phase CML Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Treatment for Accelerated-Phase CML Sales by Region
  9. 3.4.1 Global Treatment for Accelerated-Phase CML Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Treatment for Accelerated-Phase CML Sales by Region (2021-2026)
  11. 3.4.3 Global Treatment for Accelerated-Phase CML Sales by Region (2027-2032)
  12. 3.4.4 Global Treatment for Accelerated-Phase CML Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Treatment for Accelerated-Phase CML Revenue by Manufacturers
  2. 4.1.1 Global Treatment for Accelerated-Phase CML Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Treatment for Accelerated-Phase CML Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Treatment for Accelerated-Phase CML Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Treatment for Accelerated-Phase CML Sales by Manufacturers
  6. 4.2.1 Global Treatment for Accelerated-Phase CML Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Treatment for Accelerated-Phase CML Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Treatment for Accelerated-Phase CML Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Treatment for Accelerated-Phase CML Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Treatment for Accelerated-Phase CML Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Treatment for Accelerated-Phase CML Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Treatment for Accelerated-Phase CML Manufacturers, Product Type & Application
  13. 4.7 Global Treatment for Accelerated-Phase CML Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Treatment for Accelerated-Phase CML Market CR5 and HHI
  16. 4.8.2 2025 Treatment for Accelerated-Phase CML Tier 1, Tier 2, and Tier 3
5 Treatment for Accelerated-Phase CML Market by Type
  1. 5.1 Global Treatment for Accelerated-Phase CML Revenue by Type
  2. 5.1.1 Global Treatment for Accelerated-Phase CML Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Treatment for Accelerated-Phase CML Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Treatment for Accelerated-Phase CML Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Treatment for Accelerated-Phase CML Sales by Type
  6. 5.2.1 Global Treatment for Accelerated-Phase CML Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Treatment for Accelerated-Phase CML Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Treatment for Accelerated-Phase CML Sales Market Share by Type (2021-2032)
  9. 5.3 Global Treatment for Accelerated-Phase CML Price by Type
6 Treatment for Accelerated-Phase CML Market by Application
  1. 6.1 Global Treatment for Accelerated-Phase CML Revenue by Application
  2. 6.1.1 Global Treatment for Accelerated-Phase CML Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Treatment for Accelerated-Phase CML Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Treatment for Accelerated-Phase CML Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Treatment for Accelerated-Phase CML Sales by Application
  6. 6.2.1 Global Treatment for Accelerated-Phase CML Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Treatment for Accelerated-Phase CML Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Treatment for Accelerated-Phase CML Sales Market Share by Application (2021-2032)
  9. 6.3 Global Treatment for Accelerated-Phase CML Price by Application
7 Company Profiles
  1. 7.1 Apotex
  2. 7.1.1 Apotex Company Information
  3. 7.1.2 Apotex Business Overview
  4. 7.1.3 Apotex Treatment for Accelerated-Phase CML Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Apotex Treatment for Accelerated-Phase CML Product Portfolio
  6. 7.1.5 Apotex Recent Developments
  7. 7.2 Bristol Myers Squibb
  8. 7.2.1 Bristol Myers Squibb Company Information
  9. 7.2.2 Bristol Myers Squibb Business Overview
  10. 7.2.3 Bristol Myers Squibb Treatment for Accelerated-Phase CML Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Bristol Myers Squibb Treatment for Accelerated-Phase CML Product Portfolio
  12. 7.2.5 Bristol Myers Squibb Recent Developments
  13. 7.3 Dr. Reddy's Laboratories
  14. 7.3.1 Dr. Reddy's Laboratories Company Information
  15. 7.3.2 Dr. Reddy's Laboratories Business Overview
  16. 7.3.3 Dr. Reddy's Laboratories Treatment for Accelerated-Phase CML Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Dr. Reddy's Laboratories Treatment for Accelerated-Phase CML Product Portfolio
  18. 7.3.5 Dr. Reddy's Laboratories Recent Developments
  19. 7.4 Novartis
  20. 7.4.1 Novartis Company Information
  21. 7.4.2 Novartis Business Overview
  22. 7.4.3 Novartis Treatment for Accelerated-Phase CML Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Novartis Treatment for Accelerated-Phase CML Product Portfolio
  24. 7.4.5 Novartis Recent Developments
  25. 7.5 Pfizer
  26. 7.5.1 Pfizer Company Information
  27. 7.5.2 Pfizer Business Overview
  28. 7.5.3 Pfizer Treatment for Accelerated-Phase CML Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Pfizer Treatment for Accelerated-Phase CML Product Portfolio
  30. 7.5.5 Pfizer Recent Developments
  31. 7.6 Takeda Pharmaceuticals
  32. 7.6.1 Takeda Pharmaceuticals Company Information
  33. 7.6.2 Takeda Pharmaceuticals Business Overview
  34. 7.6.3 Takeda Pharmaceuticals Treatment for Accelerated-Phase CML Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Takeda Pharmaceuticals Treatment for Accelerated-Phase CML Product Portfolio
  36. 7.6.5 Takeda Pharmaceuticals Recent Developments
  37. 7.7 Lunan Pharmaceutical
  38. 7.7.1 Lunan Pharmaceutical Company Information
  39. 7.7.2 Lunan Pharmaceutical Business Overview
  40. 7.7.3 Lunan Pharmaceutical Treatment for Accelerated-Phase CML Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Lunan Pharmaceutical Treatment for Accelerated-Phase CML Product Portfolio
  42. 7.7.5 Lunan Pharmaceutical Recent Developments
  43. 7.8 Qilu Pharmaceutical
  44. 7.8.1 Qilu Pharmaceutical Company Information
  45. 7.8.2 Qilu Pharmaceutical Business Overview
  46. 7.8.3 Qilu Pharmaceutical Treatment for Accelerated-Phase CML Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Qilu Pharmaceutical Treatment for Accelerated-Phase CML Product Portfolio
  48. 7.8.5 Qilu Pharmaceutical Recent Developments
  49. 7.9 CSPC Ouyi Pharmaceutical
  50. 7.9.1 CSPC Ouyi Pharmaceutical Company Information
  51. 7.9.2 CSPC Ouyi Pharmaceutical Business Overview
  52. 7.9.3 CSPC Ouyi Pharmaceutical Treatment for Accelerated-Phase CML Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 CSPC Ouyi Pharmaceutical Treatment for Accelerated-Phase CML Product Portfolio
  54. 7.9.5 CSPC Ouyi Pharmaceutical Recent Developments
  55. 7.10 Chia Tai Tianqing Pharmaceutical
  56. 7.10.1 Chia Tai Tianqing Pharmaceutical Company Information
  57. 7.10.2 Chia Tai Tianqing Pharmaceutical Business Overview
  58. 7.10.3 Chia Tai Tianqing Pharmaceutical Treatment for Accelerated-Phase CML Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Chia Tai Tianqing Pharmaceutical Treatment for Accelerated-Phase CML Product Portfolio
  60. 7.10.5 Chia Tai Tianqing Pharmaceutical Recent Developments
8 North America
  1. 8.1 North America Treatment for Accelerated-Phase CML Market Size by Type
  2. 8.1.1 North America Treatment for Accelerated-Phase CML Revenue by Type (2021-2032)
  3. 8.1.2 North America Treatment for Accelerated-Phase CML Sales by Type (2021-2032)
  4. 8.1.3 North America Treatment for Accelerated-Phase CML Price by Type (2021-2032)
  5. 8.2 North America Treatment for Accelerated-Phase CML Market Size by Application
  6. 8.2.1 North America Treatment for Accelerated-Phase CML Revenue by Application (2021-2032)
  7. 8.2.2 North America Treatment for Accelerated-Phase CML Sales by Application (2021-2032)
  8. 8.2.3 North America Treatment for Accelerated-Phase CML Price by Application (2021-2032)
  9. 8.3 North America Treatment for Accelerated-Phase CML Market Size by Country
  10. 8.3.1 North America Treatment for Accelerated-Phase CML Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Treatment for Accelerated-Phase CML Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Treatment for Accelerated-Phase CML Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Treatment for Accelerated-Phase CML Market Size by Type
  2. 9.1.1 Europe Treatment for Accelerated-Phase CML Revenue by Type (2021-2032)
  3. 9.1.2 Europe Treatment for Accelerated-Phase CML Sales by Type (2021-2032)
  4. 9.1.3 Europe Treatment for Accelerated-Phase CML Price by Type (2021-2032)
  5. 9.2 Europe Treatment for Accelerated-Phase CML Market Size by Application
  6. 9.2.1 Europe Treatment for Accelerated-Phase CML Revenue by Application (2021-2032)
  7. 9.2.2 Europe Treatment for Accelerated-Phase CML Sales by Application (2021-2032)
  8. 9.2.3 Europe Treatment for Accelerated-Phase CML Price by Application (2021-2032)
  9. 9.3 Europe Treatment for Accelerated-Phase CML Market Size by Country
  10. 9.3.1 Europe Treatment for Accelerated-Phase CML Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Treatment for Accelerated-Phase CML Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Treatment for Accelerated-Phase CML Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Treatment for Accelerated-Phase CML Market Size by Type
  2. 10.1.1 China Treatment for Accelerated-Phase CML Revenue by Type (2021-2032)
  3. 10.1.2 China Treatment for Accelerated-Phase CML Sales by Type (2021-2032)
  4. 10.1.3 China Treatment for Accelerated-Phase CML Price by Type (2021-2032)
  5. 10.2 China Treatment for Accelerated-Phase CML Market Size by Application
  6. 10.2.1 China Treatment for Accelerated-Phase CML Revenue by Application (2021-2032)
  7. 10.2.2 China Treatment for Accelerated-Phase CML Sales by Application (2021-2032)
  8. 10.2.3 China Treatment for Accelerated-Phase CML Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Treatment for Accelerated-Phase CML Market Size by Type
  2. 11.1.1 Asia Treatment for Accelerated-Phase CML Revenue by Type (2021-2032)
  3. 11.1.2 Asia Treatment for Accelerated-Phase CML Sales by Type (2021-2032)
  4. 11.1.3 Asia Treatment for Accelerated-Phase CML Price by Type (2021-2032)
  5. 11.2 Asia Treatment for Accelerated-Phase CML Market Size by Application
  6. 11.2.1 Asia Treatment for Accelerated-Phase CML Revenue by Application (2021-2032)
  7. 11.2.2 Asia Treatment for Accelerated-Phase CML Sales by Application (2021-2032)
  8. 11.2.3 Asia Treatment for Accelerated-Phase CML Price by Application (2021-2032)
  9. 11.3 Asia Treatment for Accelerated-Phase CML Market Size by Country
  10. 11.3.1 Asia Treatment for Accelerated-Phase CML Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Treatment for Accelerated-Phase CML Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Treatment for Accelerated-Phase CML Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Treatment for Accelerated-Phase CML Market Size by Type
  2. 12.1.1 SAMEA Treatment for Accelerated-Phase CML Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Treatment for Accelerated-Phase CML Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Treatment for Accelerated-Phase CML Price by Type (2021-2032)
  5. 12.2 SAMEA Treatment for Accelerated-Phase CML Market Size by Application
  6. 12.2.1 SAMEA Treatment for Accelerated-Phase CML Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Treatment for Accelerated-Phase CML Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Treatment for Accelerated-Phase CML Price by Application (2021-2032)
  9. 12.3 SAMEA Treatment for Accelerated-Phase CML Market Size by Country
  10. 12.3.1 SAMEA Treatment for Accelerated-Phase CML Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Treatment for Accelerated-Phase CML Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Treatment for Accelerated-Phase CML Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Treatment for Accelerated-Phase CML Value Chain Analysis
  2. 13.1.1 Treatment for Accelerated-Phase CML Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Treatment for Accelerated-Phase CML Production Mode & Process
  6. 13.2 Treatment for Accelerated-Phase CML Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Treatment for Accelerated-Phase CML Distributors
  9. 13.2.3 Treatment for Accelerated-Phase CML Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst